drugset / Trial / NCT02585596

A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.

NCT02585596

Phase 2 Completed 275 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the efficacy and the safety of YH23537 in Korea patients with chronic periodontitis, in order to investigate the recommended therapeutic dose.

Timeline

Start
2015-12-16
Primary completion
2016-12-28
Completion
2017-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject YH23537 Unknown 1000 mg Oral
Subject YH23537 Unknown 2000 mg Oral
Subject YH23537 Unknown 3000 mg Oral

Indications